Functional_JJ Heterogeneity_NN of_IN Bone_NP Morphogenetic_NP Protein_NP Receptor-II_NP Mutants_NP Found_NP in_IN Patients_NPS with_IN Primary_NP Pulmonary_NP Hypertension_NP Germline_NP mutations_NNS in_IN the_DT BMPR2_NP gene_NN encoding_VBG bone_NN morphogenetic_JJ protein_NN (_( BMP_NP )_) type_NN II_CD receptor_NN (_( BMPR-II_NP )_) have_VBP been_VBN reported_VBN in_IN patients_NNS with_IN primary_JJ pulmonary_JJ hypertension_NN (_( PPH_NP )_) ,_, but_CC the_DT contribution_NN of_IN various_JJ types_NNS of_IN mutations_NNS found_VBN in_IN PPH_NP to_TO the_DT pathogenesis_NN of_IN clinical_JJ phenotypes_NNS has_VBZ not_RB been_VBN elucidated_VBN ._SENT To_TO determine_VB the_DT biological_JJ activities_NNS of_IN these_DT mutants_NNS ,_, we_PP performed_VBD functional_JJ assays_NNS testing_VBG their_PP$ abilities_NNS to_TO transduce_VB BMP_NN signals_NNS ._SENT We_PP found_VBD that_IN the_DT reported_VBN missense_NN mutations_NNS within_IN the_DT extracellular_JJ and_CC kinase_NN domains_NNS of_IN BMPR-II_NP abrogated_VBD their_PP$ signal-transducing_NN abilities_NNS ._SENT BMPR-II_NP proteins_NNS containing_VBG mutations_NNS at_IN the_DT conserved_VBN cysteine_NN residues_NNS in_IN the_DT extracellular_JJ and_CC kinase_NN domains_NNS were_VBD detected_VBN in_IN the_DT cytoplasm_NN ,_, suggesting_VBG that_IN the_DT loss_NN of_IN signaling_VBG ability_NN of_IN certain_JJ BMPR-II_NP mutants_NNS is_VBZ due_JJ at_IN least_JJS in_IN part_NN to_TO their_PP$ altered_JJ subcellular_JJ localization_NN ._SENT In_IN contrast_NN ,_, BMPR-II_NP mutants_NNS with_IN truncation_NN of_IN the_DT cytoplasmic_JJ tail_NN retained_VBD the_DT ability_NN to_TO transduce_VB BMP_NN signals_NNS ._SENT The_DT differences_NNS in_IN biological_JJ activities_NNS among_IN the_DT BMPR-II_NP mutants_NNS observed_VBD thus_RB suggest_VB that_IN additional_JJ genetic_JJ and/or_CC environmental_JJ factors_NNS may_MD play_VB critical_JJ roles_NNS in_IN the_DT pathogenesis_NN of_IN PPH_NP ._SENT Vascular_JJ development_NN and_CC homeostasis_NN are_VBP regulated_VBN by_IN a_DT number_NN of_IN cytokines_NNS ,_, including_VBG the_DT members_NNS of_IN the_DT transforming_VBG growth_NN factor-beta_NN (_( TGF-beta_NP )_) superfamily_NN ._SENT The_DT TGF-beta_NP superfamily_NN includes_VBZ various_JJ proteins_NNS with_IN similar_JJ dimeric_JJ structures_NNS ,_, e.g._FW ,_, activins_NNS ,_, nodal_JJ ,_, bone_VB morphogenetic_JJ proteins_NNS (_( BMPs_NP )_) ,_, and_CC growth/differentiation_NN factors_NNS ._SENT BMPs_NNS were_VBD originally_RB identified_VBN as_IN osteoinductive_JJ cytokines_NNS at_IN extraskeletal_JJ sites_NNS in_IN vivo_RB ._SENT Subsequently_RB ,_, BMPs_NNS have_VBP been_VBN shown_VBN to_TO exhibit_VB multifunctional_JJ activities_NNS in_IN various_JJ types_NNS of_IN cells_NNS ._SENT They_PP regulate_VBP cell_NN growth_NN ,_, apoptosis_NN ,_, and_CC differentiation_NN ,_, and_CC participate_VB in_IN patterning_NN and_CC specification_NN of_IN various_JJ tissues_NNS and_CC organs_NNS ._SENT BMPs_NNS transduce_VBP their_PP$ signals_NNS via_IN two_CD types_NNS of_IN serine/threonine_JJ kinase_NN receptors_NNS ,_, type_NN I_PP and_CC type_VB II_NP receptors_NNS ,_, both_CC of_IN which_WDT are_VBP required_VBN for_IN their_PP$ signal_NN transduction_NN ._SENT BMPs_NP bind_NN to_TO three_CD different_JJ type_NN II_NP receptors_NNS ,_, i.e._FW ,_, activin_NN type_NN II_CD receptors_NNS (_( ActR-IIA_NP and_CC ActR-IIB_NP )_) and_CC BMPR-II_NP ,_, and_CC three_CD different_JJ type_NN I_PP receptors_NNS ,_, i.e._FW ,_, activin_JJ receptor-like_JJ kinase_NN (ALK)-3/BMPR-IA_NN ,_, ALK-6/BMPR-IB_NP ,_, and_CC ALK-2_NP (_( ,_, ;_: ;_: ;_: ;_: )_) ._SENT On_IN binding_VBG of_IN BMPs_NP ,_, type_NN II_CD receptors_NNS phosphorylate_JJ type_NN I_PP receptors_NNS ,_, which_WDT in_RB turn_VBP phosphorylate_JJ intracellular_JJ signal-transducing_NN molecules_NNS Smad1_NP ,_, 5_CD ,_, and_CC 8_CD ._SENT ALK-3_NP and_CC ALK-6_NP activate_VBP these_DT three_CD Smads_NNS ,_, whereas_IN ALK-2_NP activates_VBZ only_JJ Smad1_NP and_CC Smad5_NP but_CC not_RB Smad8_NP ._SENT Recently_RB ,_, heterozygous_JJ germline_NN mutations_NNS of_IN the_DT BMPR2_NP gene_NN encoding_VBG BMPR-II_NP were_VBD found_VBN in_IN patients_NNS with_IN primary_JJ pulmonary_JJ hypertension_NN (_( PPH_NP )_) ,_, suggesting_VBG that_IN BMPs_NP may_MD play_VB important_JJ roles_NNS in_IN homeostasis_NN of_IN the_DT pulmonary_JJ vascular_JJ system_NN ._SENT PPH_NP is_VBZ a_DT disorder_NN of_IN the_DT pulmonary_JJ arteries_NNS characterized_VBN by_IN formation_NN of_IN plexiform_JJ lesions_NNS and_CC obliteration_NN of_IN small_JJ pulmonary_JJ arteries_NNS ._SENT Subsequently_RB ,_, sporadic_JJ form_NN of_IN PPH_NP was_VBD also_RB shown_VBN to_TO be_VB associated_VBN with_IN germline_NN mutations_NNS of_IN BMPR2_NP in_IN at_IN least_JJS 26_CD %_NN of_IN cases_NNS ._SENT Although_IN BMP_NN signals_NNS are_VBP involved_VBN in_IN the_DT regulation_NN of_IN proliferation_NN of_IN human_JJ pulmonary_JJ smooth_JJ muscle_NN cells_NNS ,_, it_PP has_VBZ not_RB been_VBN determined_VBN whether_IN all_DT cases_NNS of_IN PPH_NP carrying_VBG mutations_NNS within_IN the_DT BMPR2_NP gene_NN are_VBP caused_VBN by_IN perturbation_NN of_IN BMP_NN signals_NNS ._SENT Mutations_NNS are_VBP distributed_VBN throughout_IN the_DT coding_VBG region_NN of_IN the_DT BMPR2_NP gene_NN ,_, suggesting_VBG heterogeneity_NN of_IN their_PP$ contribution_NN to_TO the_DT pathogenesis_NN of_IN PPH_NP ._SENT Furthermore_RB ,_, many_JJ PPH_NN kindreds_NNS carrying_VBG mutations_NNS of_IN the_DT BMPR2_NP gene_NN do_VBP not_RB develop_VB any_DT signs_NNS or_CC symptoms_NNS ,_, suggesting_VBG that_IN additional_JJ environmental_JJ and/or_CC genetic_JJ factors_NNS may_MD be_VB necessary_JJ for_IN development_NN of_IN symptoms_NNS ._SENT These_DT findings_NNS raised_VBD the_DT following_VBG questions_NNS :_: 1_LS )_) whether_IN the_DT signaling_VBG components_NNS of_IN BMP/Smad_NP pathways_NNS are_VBP present_JJ in_IN human_JJ pulmonary_JJ endothelial_JJ and_CC smooth_JJ muscle_NN cells_NNS ,_, 2_LS )_) whether_IN BMP_NN signals_NNS are_VBP impaired_VBN by_IN all_DT types_NNS of_IN mutations_NNS found_VBN in_IN PPH_NN patients_NNS ,_, and_CC 3_LS )_) how_WRB signal-transducing_NN capabilities_NNS are_VBP disrupted_VBN in_IN the_DT BMPR-II_NP mutant_JJ proteins_NNS ._SENT In_IN this_DT study_NN ,_, we_PP used_VBD various_JJ types_NNS of_IN BMPR-II_NP mutants_NNS found_VBD in_IN patients_NNS with_IN PPH_NP to_TO investigate_VB their_PP$ ability_NN to_TO transduce_VB BMP_NN signals_NNS and_CC the_DT biochemical_JJ mechanisms_NNS by_IN which_WDT BMPR-II_NP mutants_NNS interfere_VBP with_IN BMP_NN signaling_VBG ._SENT First_RB ,_, we_PP showed_VBD that_IN human_JJ pulmonary_JJ artery_NN endothelial_JJ cells_NNS (_( HPAECs_NP )_) and_CC smooth_JJ muscle_NN cells_NNS (_( PASMCs_NP )_) expressed_VBD BMP/TGF-beta_NP signaling_VBG components_NNS ,_, suggesting_VBG that_IN these_DT cells_NNS may_MD potentially_RB transduce_VB their_PP$ signals_NNS ._SENT Next_RB ,_, we_PP showed_VBD that_IN some_DT BMPR-II_NP mutants_NNS lost_VBD most_RBS signal-transducing_JJ abilities_NNS ,_, such_JJ as_IN transcriptional_JJ activity_NN and_CC phosphorylation_NN of_IN Smad_NP proteins_NNS ,_, whereas_IN others_NNS retained_VBD most_JJS of_IN them_PP ._SENT Some_DT of_IN the_DT mutants_NNS with_IN defects_NNS in_IN signaling_VBG activities_NNS were_VBD predominantly_RB located_VBN in_IN cytoplasm_NN and_CC may_MD bind_VB a_DT cytoplasmic_JJ pool_NN of_IN type_NN I_PP receptors_NNS ._SENT Taken_VBN together_RB ,_, the_DT findings_NNS of_IN the_DT present_JJ study_NN suggest_VBP that_DT perturbation_NN of_IN BMP_NN signaling_VBG in_IN the_DT pulmonary_JJ vascular_JJ system_NN by_IN some_DT types_NNS of_IN mutations_NNS may_MD be_VB involved_VBN in_IN the_DT pathogenesis_NN of_IN PPH_NP ,_, whereas_IN with_IN other_JJ types_NNS of_IN mutations_NNS signals_NNS can_MD still_RB be_VB transduced_VBN ,_, suggesting_VBG that_IN additional_JJ factors_NNS may_MD be_VB required_VBN for_IN the_DT development_NN of_IN PPH_NP ._SENT Cell_NN Culture_NP |_SYM HPAECs_NP and_CC PASMCs_NP were_VBD obtained_VBN from_IN Clonetics_NP (_( San_NP Diego_NP ,_, CA_NP )_) and_CC were_VBD maintained_VBN in_IN EGM-2_NP and_CC SmGM-2_NP (_( Clonetics_NP )_) ,_, respectively_RB ._SENT COS-7_JJ and_CC R-mutant_JJ mink_NN lung_NN epithelial_JJ cells_NNS were_VBD maintained_VBN in_IN DMEM_NP (_( Sigma-Aldrich_NP ,_, St._NP Louis_NP ,_, MO_NP )_) containing_VBG 10_CD %_NN fetal_JJ bovine_JJ serum_NN ,_, 100_CD U/ml_NP penicillin_NN ,_, and_CC 100_CD mug/ml_NN streptomycin_NN ._SENT Reverse_VB Transcription-Polymerase_NP Chain_NP Reaction_NP (_( RT-PCR_NP )_) Analysis_NP |_SYM Total_JJ RNA_NP was_VBD isolated_VBN from_IN HPAECs_NP and_CC PASMCs_NP with_IN ISOGEN_NP (_( NipponGene_NP ,_, Tokyo_NP ,_, Japan_NP )_) ,_, and_CC first-strand_NN cDNA_NN was_VBD synthesized_VBN using_VBG the_DT Superscript_NN First-Strand_NP Synthesis_NP System_NP (_( Invitrogen_NP ,_, Carlsbad_NP ,_, CA_NP )_) with_IN random_JJ hexamer_NN primers_NNS ._SENT Expression_NN of_IN various_JJ signaling_VBG components_NNS was_VBD compared_VBN by_IN semiquantitative_JJ RT-PCR_NP analysis_NN ._SENT A_DT human_JJ beta-actin_NN primer_NN set_NN was_VBD used_VBN to_TO normalize_VB the_DT amount_NN of_IN total_JJ cDNA_NN in_IN each_DT sample_NN ._SENT PCR_NP products_NNS were_VBD separated_VBN by_IN electrophoresis_NN in_IN agarose_JJ gel_NN (_( 1_CD %_NN )_) and_CC visualized_VBN with_IN ethidium_NN bromide_NN ._SENT The_DT primer_NN sequences_NNS ,_, PCR_NP programs_NNS ,_, and_CC expected_VBN sizes_NNS of_IN PCR_NP products_NNS are_VBP available_JJ online_JJ as_RB indicated_VBN in_IN Table_NP 1_CD ._SENT As_IN controls_NNS ,_, RNAs_NP from_IN HPAECs_NP and_CC PASMCs_NP were_VBD analyzed_VBN for_IN beta-actin_NN expression_NN without_IN the_DT prior_JJ generation_NN of_IN cDNA_NN ,_, and_CC a_DT PCR_NP reaction_NN for_IN each_DT set_NN of_IN primers_NNS was_VBD run_VBN against_IN H2O_NP ._SENT Plasmid_NP Construction_NP |_SYM Plasmids_NNS of_IN the_DT BMPR-II_NP ,_, ALKs_NP ,_, and_CC Smads_NNS were_VBD described_VBN previously_RB ._SENT Various_JJ mutant_JJ forms_NNS of_IN BMPR-II_NP were_VBD constructed_VBN by_IN a_DT PCR-based_JJ approach_NN ._SENT An_DT EcoRI_NP and_CC an_DT XhoI_NP site_NN were_VBD added_VBN to_TO the_DT N_NP terminus_NN and_CC C_NN terminus_NN of_IN the_DT BMPR-II_NP cDNA_NN ,_, respectively_RB ,_, and_CC the_DT resulting_VBG fragments_NNS were_VBD subcloned_VBN into_IN pcDNA3-FLAG_NN and_CC pcDNA3-HA_NN ,_, which_WDT add_VBP a_DT FLAG-tag_NP and_CC hemagglutinin_NN (HA)-tag_NN ,_, respectively_RB ,_, C-terminally_RB to_TO the_DT insert_NN ._SENT To_TO increase_VB levels_NNS of_IN expression_NN ,_, inserts_NNS were_VBD subcloned_VBN into_IN another_DT expression_NN vector_NN ,_, pcDEF3_NN ._SENT All_DT of_IN the_DT PCR_NP products_NNS were_VBD sequenced_JJ ._SENT The_DT sequences_NNS of_IN the_DT mutagenesis_NN primers_NNS are_VBP available_JJ upon_IN request_NN ._SENT Transfection_NP ,_, Immunoprecipitation_NP ,_, and_CC Immunoblotting_NP |_SYM COS-7_JJ cells_NNS were_VBD transiently_RB transfected_VBN using_VBG FuGENE6_NP (_( Roche_NP Applied_NP Science_NP ,_, Mannheim_NP ,_, Germany_NP )_) ._SENT The_DT amounts_NNS of_IN plasmids_NNS transfected_VBN are_VBP available_JJ online_JJ in_IN Table_NP 2_CD ._SENT Immunoprecipitation_NN and_CC immunoblotting_NN were_VBD performed_VBN as_IN described_VBN previously_RB using_VBG anti-HA_NP 12CA5_NP (_( for_IN immunoprecipitation_NN ;_: Roche_NP Applied_NP Science_NP )_) ,_, anti-HA_NP 3F10_NP (_( for_IN immunoblotting_NN ;_: Roche_NP Applied_NP Science_NP )_) ,_, anti-FLAG_NP M2_NP (_( Sigma-Aldrich_NP )_) ,_, and_CC anti-phosphoserine_JJ antibodies_NNS (_( Zymed_NP Laboratories_NP ,_, South_NP San_NP Francisco_NP ,_, CA_NP )_) ._SENT Luciferase_NP Assay_NP |_SYM R-mutant_JJ mink_NN lung_NN epithelial_JJ cells_NNS were_VBD transiently_RB transfected_VBN with_IN an_DT appropriate_JJ combination_NN of_IN reporter_NN constructs_NNS ,_, expression_NN plasmids_NNS ,_, and_CC pcDNA3_NN ._SENT Total_JJ amounts_NNS of_IN transfected_JJ DNAs_NP were_VBD the_DT same_JJ in_IN each_DT experiment_NN ._SENT Luciferase_NN activities_NNS were_VBD normalized_VBN using_VBG cotransfected_JJ sea_NN pansy_JJ luciferase_NN activity_NN under_IN the_DT control_NN of_IN thymidine_NN kinase_NN promoter_NN ._SENT Affinity_NN Cross-Linking_NP and_CC Immunoprecipitation_NP |_SYM Iodination_NN of_IN BMP-6_NP ,_, affinity_NN cross-linking_NN ,_, and_CC subsequent_JJ immunoprecipitation_NN were_VBD performed_VBN as_IN described_VBN previously_RB ._SENT Briefly_RB ,_, recombinant_JJ BMP-6_NP was_VBD iodinated_VBN using_VBG the_DT chloramine_NN T_NN method_NN ,_, and_CC cross-linking_NN was_VBD performed_VBN with_IN disuccinimidyl_NN suberate_NNS (_( ,_, Rockford_NP ,_, IL_NP )_) ._SENT Cells_NNS were_VBD lysed_VBN and_CC subjected_VBN to_TO immunoprecipitation_NN with_IN anti-FLAG_NN antibody_NN followed_VBN by_IN SDS-PAGE_NP ._SENT Cross-linked_JJ receptor_NN complexes_NNS were_VBD visualized_VBN by_IN using_VBG a_DT BAS_NP 1800_CD Bio-Image_NP Analyzer_NP (_( Fuji_NP Photo_NP Film_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT Immunofluorescence_NP Labeling_NP |_SYM Immunohistochemical_JJ staining_VBG of_IN FLAG-tagged_NP BMPR-II_NP in_IN transiently_RB transfected_JJ COS-7_JJ cells_NNS was_VBD performed_VBN using_VBG anti-FLAG_NP M2_NP antibody_NN (_( Sigma-Aldrich_NP )_) ,_, followed_VBN by_IN incubation_NN with_IN fluorescein_NN isothiocyanate-labeled_JJ goat_NN anti-mouse_NN IgG_NP as_RB described_VBD previously_RB ._SENT Nuclei_NNS of_IN the_DT cells_NNS were_VBD stained_VBN by_IN 4,6-diamidino-2-phenylindole_JJ ._SENT Subcellular_JJ localization_NN was_VBD determined_VBN by_IN confocal_JJ laser_NN scanning_VBG microscopy_NN (_( ,_, Hercules_NP ,_, CA_NP )_) ._SENT Profiles_NNS of_IN Expression_NP of_IN TGF-beta_NP Superfamily_NP Signaling_NP Components_NP in_IN Pulmonary_NP Vascular_NP Cells_NP |_SYM Recently_RB ,_, showed_VBD that_IN PASMCs_NP express_VB type_NN I_PP (_( ALK-1_NP ,_, 4_CD ,_, 5_CD ,_, and_CC 6_CD )_) and_CC type_NN II_NP (_( TGF-beta_NP type_NN II_CD receptor_NN [_SYM TbetaR-II_NP ]_SYM ,_, ActR-II_NP ,_, and_CC BMPR-II_NP )_) receptors_NNS for_IN the_DT TGF-beta_NP superfamily_NN ._SENT To_TO further_RBR evaluate_VB the_DT expression_NN of_IN TGF-beta_NP superfamily_NN signaling_VBG components_NNS in_IN HPAECs_NP and_CC PASMCs_NP ,_, we_PP performed_VBD RT-PCR_NP analysis_NN to_TO detect_VB mRNA_NN transcripts_NNS for_IN ligands_NNS (_( BMP-2_NP and_CC TGF-beta1_NP )_) ,_, type_NN I_PP (_( ALK-1_NP ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, and_CC 6_CD )_) ,_, type_NN II_CD receptors_NNS (_( BMPR-II_NP ,_, ActR-IIA_NP ,_, ActR-IIB_NP ,_, and_CC TbetaR-II_NP )_) ,_, endoglin_NP ,_, betaglycan_NN ,_, and_CC Smads_NP (_( Smad1_NP ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, and_CC 5_CD )_) ._SENT Figure_NP 1_CD |_SYM Expression_NN of_IN TGF-beta_NP superfamily_NN signaling_VBG components_NNS in_IN HPAECs_NP and_CC PASMCs_NP ._SENT Expression_NN of_IN TGF-beta_NP superfamily_NN signaling_VBG components_NNS in_IN HPAECs_NP and_CC PASMCs_NP ._SENT RNA_NP samples_NNS from_IN HPAECs_NP and_CC PASMCs_NP were_VBD analyzed_VBN by_IN RT-PCR_NP for_IN expression_NN of_IN TGF-beta_NP superfamily-signaling_NN components_NNS and_CC the_DT housekeeping_NN gene_NN beta-actin_NN ._SENT Two_CD alternatively_RB spliced_VBN forms_NNS ,_, WT_NP and_CC SH_NP ,_, of_IN BMPR-II_NP mRNA_NP transcripts_NNS were_VBD detected_VBN ._SENT As_IN controls_NNS ,_, RNAs_NP from_IN HPAECs_NP and_CC PASMCs_NP were_VBD analyzed_VBN for_IN beta-actin_NN expression_NN without_IN the_DT prior_JJ generation_NN of_IN cDNA_NN ,_, and_CC a_DT PCR_NP reaction_NN for_IN each_DT set_NN of_IN primers_NNS was_VBD run_VBN against_IN H2O_NP ._SENT Transcripts_NNS for_IN both_DT BMP-2_NP and_CC TGF-beta1_NP were_VBD present_JJ in_IN HPAECs_NP and_CC PASMCs_NP ._SENT Among_IN BMP_NN type_NN I_PP receptors_NNS ,_, ALK-2_NP and_CC ALK-6_NP were_VBD expressed_VBN in_IN both_DT types_NNS of_IN cells_NNS ,_, whereas_IN ALK-3_NP was_VBD expressed_VBN only_RB in_IN PASMCs_NP ._SENT ALK-1_NP is_VBZ a_DT TGF-beta_NP type_NN I_NP receptor_NN that_WDT has_VBZ been_VBN reported_VBN to_TO be_VB predominantly_RB expressed_VBN in_IN endothelial_JJ cells_NNS ._SENT We_PP detected_VBD mRNA_NN transcripts_NNS for_IN ALK-1_NP in_IN HPAECs_NP but_CC only_RB very_RB weakly_JJ in_IN PASMCs_NP ,_, whereas_IN we_PP detected_VBD those_DT for_IN ALK-5_NP in_IN both_DT types_NNS of_IN cells_NNS ._SENT Two_CD alternatively_RB spliced_VBN forms_NNS of_IN BMPR-II_NP mRNA_NP transcripts_NNS have_VBP been_VBN reported_VBN ._SENT To_TO examine_VB which_WDT forms_NNS of_IN BMPR-II_NP are_VBP expressed_VBN in_IN pulmonary_JJ vascular_JJ cells_NNS ,_, we_PP designed_VBD PCR_NP primers_NNS that_WDT are_VBP able_JJ to_TO generate_VB distinct_JJ PCR_NP products_NNS from_IN the_DT two_CD spliced_VBN variants_NNS ._SENT As_IN shown_VBN in_IN Figure_NN ,_, transcripts_NNS for_IN both_CC the_DT wild-type_NN (_( WT_NP )_) and_CC short_JJ (_( SH_NP )_) form_NN of_IN BMPR-II_NP were_VBD detected_VBN in_IN both_DT types_NNS of_IN cells_NNS ,_, although_IN intensities_NNS of_IN the_DT bands_NNS of_IN BMPR-II_NP (_( SH_NP )_) were_VBD much_RB weaker_JJR than_IN those_DT of_IN BMPR-II_NP (_( WT_NP )_) for_IN both_DT types_NNS of_IN cells_NNS ._SENT We_PP also_RB detected_VBD transcripts_NNS for_IN other_JJ type_NN II_NP receptors_NNS ,_, i.e._FW ,_, ActR-IIA_NNS ,_, ActR-IIB_NP ,_, and_CC TbetaR-II_NP ,_, and_CC endoglin_NN and_CC betaglycan_NN in_IN both_DT types_NNS of_IN cells_NNS ._SENT Finally_RB ,_, the_DT expression_NN of_IN Smads_NNS was_VBD examined_VBN in_IN HPAECs_NP and_CC PASMCs_NP ._SENT We_PP detected_VBD mRNA_NN transcripts_NNS for_IN receptor-regulated_JJ Smads_NNS specific_JJ for_IN BMPs_NP (_( Smads_NP 1_CD ,_, 5_CD ,_, amd_RB 8_CD )_) ,_, and_CC those_DT for_IN TGF-betas_NP and_CC activins_NP (_( Smads_NP 2_CD and_CC 3_CD )_) ,_, and_CC common-partner_NP Smad_NP (_( Smad4_NP )_) ,_, in_IN both_DT of_IN the_DT cell_NN types_NNS ._SENT Thus_RB ,_, both_DT HPAECs_NP and_CC PASMCs_NP express_VBP transcripts_NNS for_IN most_JJS components_NNS of_IN BMP_NP and_CC TGF-beta_NP --_: signaling_VBG pathways_NNS ,_, suggesting_VBG that_IN pulmonary_JJ vascular_JJ cells_NNS are_VBP capable_JJ of_IN responding_VBG to_TO BMPs_NP and_CC TGF-betas_NP ._SENT However_RB ,_, responses_NNS to_TO these_DT ligands_NNS may_MD differ_VB between_IN HPAECs_NP and_CC PASMCs_NP ,_, because_IN of_IN their_PP$ differences_NNS in_IN expression_NN profiles_NNS of_IN type_NN I_PP receptors_NNS ALK-1_NP and_CC ALK-3_NP ._SENT Construction_NN of_IN BMPR-II_NP Mutants_NP Found_NP in_IN Patients_NPS with_IN PPH_NP |_SYM Because_IN it_PP seemed_VBD that_IN BMP_NN signals_NNS are_VBP intact_JJ in_IN pulmonary_JJ vascular_JJ cells_NNS ,_, we_PP attempted_VBD to_TO characterize_VB the_DT biological_JJ activities_NNS of_IN the_DT mutant_JJ forms_NNS of_IN BMPR-II_NP found_VBD in_IN patients_NNS with_IN PPH_NP ._SENT BMPR-II_NP has_VBZ a_DT structure_NN essentially_RB similar_JJ to_TO those_DT of_IN other_JJ type_NN II_CD receptors_NNS for_IN members_NNS of_IN the_DT TGF-beta_NP superfamily_NN ._SENT However_RB ,_, BMPR-II_NP (_( WT_NP )_) has_VBZ a_DT long_JJ cytoplasmic_JJ tail_NN ,_, the_DT roles_NNS of_IN which_WDT are_VBP not_RB well_RB understood_VBD (_( Figure_NP A_NP )_) ._SENT In_IN addition_NN ,_, an_DT alternatively_RB spliced_VBN form_NN (_( SH_NP )_) lacking_VBG the_DT cytoplasmic_JJ tail_NN exhibited_VBD no_DT functional_JJ differences_NNS from_IN BMPR-II_NP (_( WT_NP )_) when_WRB assayed_VBN using_VBG Xenopus_NP embryos_NNS ._SENT Figure_NP 2_CD |_SYM Biological_JJ activities_NNS of_IN wild-type_NN and_CC mutant_JJ BMPR-II_NP ._SENT Biological_JJ activities_NNS of_IN wild-type_NN and_CC mutant_JJ BMPR-II_NP ._SENT (_( A_NP )_) Structure_NN and_CC location_NN of_IN mutations_NNS of_IN WT_NP ,_, SH_NP ,_, and_CC mutant_JJ BMPR-II_NP used_VBD in_IN the_DT following_VBG experiments_NNS ._SENT Numbers_NNS indicate_VBP amino_NN acid_NN positions_NNS ._SENT Mutations_NNS are_VBP denoted_VBN by_IN asterisks_NNS ._SENT Missense_NN mutations_NNS in_IN extracellular_JJ (_( E1_NP )_) and_CC kinase_NN (_( K1_NP and_CC K2_NP )_) domain_NN mutants_NNS and_CC substituted_VBN amino_NN acid_NN residues_NNS are_VBP shown_VBN ._SENT Cytoplasmic_JJ tail_JJ mutants_NNS (_( T1_NP and_CC T2_NP )_) have_VBP frameshift_NN or_CC nonsense_NN mutations_NNS resulting_VBG in_IN truncated_JJ tails_NNS ._SENT (_( B_NP and_CC C_NP )_) Transcriptional_JJ activation_NN by_IN wild-type_NN and_CC mutant_JJ BMPR-II_NP ._SENT p3TP-Lux_NP reporter_NN gene_NN was_VBD cotransfected_VBN into_IN R-mutant_JJ mink_NN lung_NN epithelial_JJ cells_NNS with_IN ALK-3_NP and_CC wild-type_NN and/or_CC mutant_JJ forms_NNS of_IN BMPR-II_NP as_RB indicated_VBD ,_, and_CC cells_NNS were_VBD stimulated_VBN with_IN or_CC without_IN BMP-2_NP (_( 100_CD ng/ml_NNS for_IN B_NP and_CC 50_CD ng/ml_NNS for_IN C_NP )_) ._SENT Luciferase_NP activity_NN was_VBD normalized_VBN against_IN cotransfected_JJ sea_NN pansy_JJ luciferase_NN activity_NN ._SENT Expression_NN of_IN cotransfected_JJ BMPR-II_NP mutants_NNS was_VBD confirmed_VBN by_IN immunoblotting_VBG of_IN cell_NN lysates_NNS with_IN anti-FLAG_NN antibodies_NNS (_( C_NP ,_, right_NN )_) ._SENT At_IN least_JJS four_CD types_NNS of_IN germline_NN mutations_NNS of_IN the_DT BMPR2_NP gene_NN have_VBP been_VBN reported_VBN ._SENT The_DT first_JJ type_NN (_( type_NN X_NN )_) has_VBZ nonsense_NN or_CC frameshift_NN mutations_NNS in_IN the_DT extracellular_JJ domain_NN ,_, which_WDT lead_VBP to_TO premature_JJ truncation_NN of_IN the_DT transcripts_NNS and_CC absence_NN of_IN the_DT production_NN of_IN transmembrane_JJ BMPR-II_NP proteins_NNS ._SENT The_DT second_JJ type_NN (_( type_NN E_NN )_) has_VBZ missense_JJ mutations_NNS in_IN the_DT extracellular_JJ domain_NN ,_, most_JJS of_IN which_WDT involve_VBP highly_RB conserved_VBN cysteine_NN residues_NNS ._SENT The_DT third_JJ type_NN (_( type_NN K_NN )_) has_VBZ either_DT missense_NN or_CC frameshift_NN mutations_NNS in_IN the_DT kinase_NN domain_NN ._SENT The_DT fourth_JJ type_NN (_( type_NN T_NN )_) has_VBZ frameshift_NN or_CC nonsense_NN mutations_NNS within_IN the_DT cytoplasmic_JJ tail_NN ,_, resulting_VBG in_IN cytoplasmic_JJ truncation_NN of_IN the_DT receptor_NN protein_NN ._SENT To_TO investigate_VB the_DT biological_JJ activities_NNS of_IN the_DT BMPR-II_NP mutants_NNS ,_, we_PP constructed_VBD one_CD or_CC two_CD of_IN each_DT of_IN the_DT three_CD types_NNS of_IN BMPR-II_NP mutant_NN (_( E1_NP ,_, K1_NP ,_, K2_NP ,_, T1_NP ,_, and_CC T2_NP )_) reported_VBD by_IN the_DT International_NP PPH_NP Consortium_NP (_( Figure_NP A_NP )_) ._SENT BMPR-II_NP Mutants_NP Found_NP in_IN PPH_NP Patients_NPS Exhibited_NP Differences_NNS in_IN Transcriptional_JJ Activities_NNS |_SYM We_PP first_RB examined_VBD the_DT transcriptional_JJ activities_NNS mediated_VBN by_IN wild-type_NN or_CC mutant_JJ forms_NNS of_IN BMPR-II_NP by_IN using_VBG p3TP-Lux_NNS ,_, a_DT TGF-beta_NP --_: responsive_JJ promoter-reporter_NN construct_NN ,_, which_WDT weakly_RB responds_VBZ to_TO BMP_NN signals_NNS ._SENT Coexpression_NN of_IN a_DT BMP_NP type_NN I_CD receptor_NN (_( ALK-3_NP )_) and_CC WT_NP or_CC SH_NP of_IN BMPR-II_NP induced_VBD transcriptional_JJ activation_NN of_IN p3TP-Lux_NNS ,_, which_WDT was_VBD further_RBR enhanced_VBN in_IN the_DT presence_NN of_IN BMP-2_NP (_( Figure_NP B_NP )_) ._SENT None_NN of_IN the_DT E1_NP ,_, K1_NP ,_, or_CC K2_NP mutants_NNS induced_VBD transcriptional_JJ activation_NN of_IN the_DT reporter_NN gene_NN ._SENT In_IN contrast_NN ,_, the_DT T1_NP and_CC T2_NP mutants_NNS maintained_VBD the_DT ability_NN to_TO induce_VB transcription_NN from_IN p3TP-Lux_NNS ,_, suggesting_VBG that_DT truncation_NN of_IN the_DT cytoplasmic_JJ tail_NN does_VBZ not_RB efficiently_RB disrupt_VB the_DT transcriptional_JJ activity_NN of_IN BMPR-II_NP ._SENT Essentially_RB similar_JJ results_NNS were_VBD obtained_VBN using_VBG 3GC2-lux_NP ,_, a_DT BMP-specific_NP promoter-reporter_NN construct_NN (_( our_PP$ unpublished_JJ data_NNS )_) ,_, suggesting_VBG that_IN the_DT transcriptional_JJ activities_NNS induced_VBN by_IN BMPR-II_NP mutants_NNS found_VBD in_IN patients_NNS with_IN PPH_NP differ_VBP between_IN the_DT type_NN E_NN and_CC K_NN mutants_NNS and_CC type_NN T_NN mutants_NNS ._SENT Because_IN heterozygous_JJ mutations_NNS of_IN the_DT BMPR2_NP gene_NN were_VBD reported_VBN to_TO cause_VB PPH_NN ,_, we_PP examined_VBD the_DT effects_NNS of_IN the_DT BMPR-II_NP mutants_NNS on_IN the_DT p3TP-Lux_NN transcriptional_JJ activity_NN induced_VBN by_IN BMPR-II_NP (_( WT_NP )_) (_( Figure_NP C_NP ,_, left_JJ )_) ._SENT When_WRB the_DT E1_NP or_CC K1_NP mutants_NNS were_VBD cotransfected_VBN with_IN BMPR-II_NP (_( WT_NP )_) ,_, they_PP repressed_VBD the_DT transcriptional_JJ activity_NN induced_VBN by_IN BMPR-II_NP (_( WT_NP )_) in_IN a_DT dose-dependent_JJ manner_NN ,_, suggesting_VBG that_IN the_DT E1_NP and_CC K1_NP mutants_NNS behave_VBP as_IN dominant_JJ negative_JJ mutants_NNS ._SENT In_IN contrast_NN ,_, the_DT T1_NP or_CC T2_NP mutant_NN that_WDT retained_VBD transcriptional_JJ activities_NNS exhibited_VBN less_RBR dominant_JJ negative_JJ effect_NN than_IN the_DT E1_NP and_CC K1_NP mutants_NNS ._SENT In_IN addition_NN ,_, the_DT K2_NP mutant_NN also_RB showed_VBD less_JJR dominant_JJ negative_JJ effect_NN ,_, suggesting_VBG the_DT functional_JJ heterogeneity_NN within_IN the_DT type_NN K_NN mutants_NNS ._SENT BMPR-II_NP Mutants_NP Differentially_NP Induce_NP Phosphorylation_NP of_IN Smad5_NP |_SYM BMP_NN receptor_NN complexes_NNS propagate_VBP signals_NNS mainly_RB through_IN phosphorylation_NN of_IN Smads_NP 1_CD ,_, 5_CD ,_, and_CC 8_CD ,_, although_IN there_EX is_VBZ evidence_NN for_IN involvement_NN of_IN Smad-independent_JJ pathways_NNS in_IN this_DT propagation_NN ._SENT To_TO elucidate_VB whether_IN the_DT differences_NNS in_IN transcriptional_JJ activities_NNS induced_VBN by_IN BMPR-II_NP mutants_NNS involve_VBP the_DT activation_NN of_IN Smads_NNS ,_, we_PP analyzed_VBD the_DT phosphorylation_NN of_IN Smad5_NP cotransfected_VBN with_IN wild-type_NN or_CC mutant_JJ forms_NNS of_IN BMPR-II_NP into_IN COS-7_JJ cells_NNS ._SENT The_DT WT_NP and_CC SH_NP forms_NNS of_IN BMPR-II_NP phosphorylated_JJ Smad5_NP ,_, whereas_IN the_DT E1_NP and_CC K1_NP mutants_NNS failed_VBD to_TO do_VB so_RB ._SENT Phosphorylation_NN of_IN Smad5_NP by_IN the_DT K2_NP mutant_NN was_VBD also_RB significantly_RB reduced_VBD (_( our_PP$ unpublished_JJ data_NNS )_) ._SENT In_IN agreement_NN with_IN the_DT transcriptional_JJ activities_NNS ,_, the_DT T1_JJ mutant_JJ phosphorylated_JJ Smad5_NN ,_, although_IN less_RBR efficiently_RB than_IN BMPR-II_NP (_( WT_NP )_) ._SENT These_DT findings_NNS suggest_VBP that_IN the_DT differences_NNS in_IN transcriptional_JJ activities_NNS mediated_VBN by_IN BMPR-II_NP mutants_NNS found_VBD in_IN PPH_NN patients_NNS are_VBP due_JJ to_TO their_PP$ abilities_NNS to_TO activate_VB BMP-specific_JJ Smads_NNS ._SENT Figure_NP 3_CD |_SYM Phosphorylation_NN of_IN FLAG-tagged_NP Smad5_NP mediated_VBD by_IN HA-tagged_JJ wild-type_NN or_CC mutant_JJ BMPR-IIs_NP in_IN transfected_JJ COS-7_JJ cells_NNS ._SENT Phosphorylation_NN of_IN FLAG-tagged_NP Smad5_NP mediated_VBD by_IN HA-tagged_JJ wild-type_NN or_CC mutant_JJ BMPR-IIs_NP in_IN transfected_JJ COS-7_JJ cells_NNS ._SENT Top_JJ ,_, cell_NN lysates_NNS were_VBD immunoprecipitated_VBN (_( IP_NP )_) with_IN anti-FLAG_NN antibody_NN followed_VBN by_IN immunoblotting_NN with_IN anti-phosphoserine_NP (_( P-Ser_NP )_) antibody_NN ._SENT Expression_NN of_IN Smad5_NP (_( middle_NN )_) and_CC BMPR-II_NP (_( bottom_NN )_) was_VBD confirmed_VBN by_IN immunoblotting_VBG of_IN cell_NN lysates_NNS with_IN anti-FLAG_NN and_CC anti-HA_NN antibodies_NNS ,_, respectively_RB ._SENT Ligand-binding_NP Abilities_NP of_IN E1_NP and_CC K1_NP Mutants_NP Are_NP Decreased_NP |_SYM To_TO investigate_VB the_DT biochemical_JJ mechanisms_NNS by_IN which_WDT the_DT E1_NP and_CC K1_NP mutants_NNS lost_VBD signal-transducing_NN abilities_NNS ,_, we_PP examined_VBD the_DT ligand-binding_JJ abilities_NNS of_IN the_DT wild-type_NN and_CC mutant_JJ forms_NNS of_IN BMPR-II_NP ._SENT COS-7_JJ cells_NNS were_VBD cotransfected_VBN with_IN ALK-3_NP and_CC wild-type_NN or_CC mutant_JJ forms_NNS of_IN BMPR-II_NP ,_, affinity_NN cross-linked_VBD using_VBG 125I-BMP-6_JJ ,_, and_CC subjected_VBN to_TO immunoprecipitation_NN by_IN using_VBG anti-FLAG_NN antibody_NN for_IN BMPR-II_NP ._SENT As_IN shown_VBN in_IN Figure_NP ,_, WT_NP ,_, SH_NP ,_, K2_NP ,_, T1_NP ,_, and_CC T2_JJ mutant_JJ receptors_NNS bound_VBN BMP-6_NP efficiently_RB in_IN the_DT presence_NN of_IN ALK-3_NP ._SENT In_IN contrast_NN ,_, the_DT E1_JJ mutant_NN carrying_VBG a_DT mutation_NN in_IN the_DT extracellular_JJ ligand-binding_NN domain_NN did_VBD not_RB bind_VB BMP-6_NP ,_, suggesting_VBG that_IN its_PP$ loss_NN of_IN ligand-binding_NN ability_NN resulted_VBN in_IN the_DT loss_NN of_IN Smad-phosphorylating_JJ ability_NN ._SENT Intriguingly_RB ,_, we_PP also_RB found_VBD significant_JJ reduction_NN of_IN the_DT ligand-binding_JJ ability_NN of_IN the_DT K1_NP mutant_NN carrying_VBG a_DT mutation_NN in_IN the_DT kinase_NN domain_NN ,_, which_WDT may_MD have_VB ,_, at_IN least_JJS in_IN part_NN ,_, caused_VBD its_PP$ loss_NN of_IN Smad-phosphorylating_JJ ability_NN ._SENT Figure_NP 4_CD |_SYM Ligand-binding_JJ abilities_NNS of_IN BMPR-II_NP mutants_NNS ._SENT Ligand-binding_NN abilities_NNS of_IN BMPR-II_NP mutants_NNS ._SENT COS-7_JJ cells_NNS were_VBD transfected_VBN with_IN FLAG-tagged_NP BMPR-II_NP (_( BMPR-II-FLAG_NP )_) and_CC HA-tagged_NP ALK-3_NP (_( ALK-3-HA_NP )_) ,_, followed_VBN by_IN affinity_NN cross-linking_NN with_IN 125I-BMP-6_JJ ,_, and_CC lysates_NNS were_VBD immunoprecipitated_VBN (_( IP_NP )_) with_IN anti-FLAG_NP M2_NP antibody_NN ._SENT Immuno-complexes_NNS were_VBD subjected_VBN to_TO SDS-PAGE_NP and_CC visualized_VBN by_IN Fuji_NP BAS_NP bio-image_NN analyzer_NN (_( top_JJ )_) ._SENT Expression_NN of_IN BMPR-II_NP (_( middle_NN )_) and_CC ALK-3_NP (_( bottom_NN )_) was_VBD confirmed_VBN by_IN immunoblotting_VBG of_IN cell_NN lysates_NNS with_IN anti-FLAG_NN and_CC anti-HA_NN antibodies_NNS ,_, respectively_RB ._SENT E1_NP and_CC K1_NP Mutants_NP Exhibit_NP Altered_NP Subcellular_NP Localization_NP |_SYM To_TO determine_VB how_WRB the_DT ligand-binding_JJ abilities_NNS of_IN the_DT E1_NP and_CC K1_NP mutants_NNS were_VBD reduced_VBN ,_, we_PP examined_VBD the_DT subcellular_JJ localization_NN of_IN wild-type_NN and_CC mutant_JJ forms_NNS of_IN BMPR-II_NP ._SENT COS-7_JJ cells_NNS transfected_VBN with_IN the_DT wild-type_NN or_CC mutant_JJ forms_NNS of_IN BMPR-II_NP were_VBD subjected_VBN to_TO immunofluorescence_VB staining_VBG ._SENT WT_NP (_( Figure_NP A_NP )_) and_CC the_DT T1_JJ mutant_NN (_( Figure_NP E_NP )_) exhibited_VBD intense_JJ staining_VBG of_IN the_DT plasma_NN membrane_NN as_RB well_RB as_IN the_DT cytoplasm_NN ._SENT In_IN contrast_NN ,_, the_DT E1_NP and_CC K1_NP mutants_NNS carrying_VBG missense_NN mutations_NNS of_IN cysteine_NN residues_NNS within_IN the_DT extracellular_JJ and_CC kinase_NN domains_NNS ,_, respectively_RB ,_, were_VBD observed_VBN mostly_RB in_IN the_DT cytoplasm_NN (_( Figure_NP ,_, B_NP and_CC C_NP )_) ,_, suggesting_VBG that_DT reduction_NN of_IN the_DT ligand_NN binding_VBG abilities_NNS of_IN the_DT E1_NP and_CC K1_NP mutants_NNS was_VBD due_JJ to_TO their_PP$ altered_JJ subcellular_JJ localization_NN ._SENT The_DT K2_NP mutant_NN ,_, carrying_VBG a_DT missense_NN mutation_NN of_IN aspartic_JJ acid_NN within_IN the_DT kinase_NN domain_NN ,_, was_VBD mainly_RB located_VBN on_IN the_DT plasma_NN membrane_NN ,_, suggesting_VBG that_IN the_DT mechanism_NN of_IN its_PP$ loss_NN of_IN signal-transducing_NN ability_NN may_MD be_VB due_JJ to_TO perturbation_NN of_IN kinase_NN activity_NN ._SENT Figure_NP 5_CD |_SYM Differential_JJ subcellular_JJ localization_NN of_IN wild-type_NN and_CC mutant_JJ BMPR-II_NP ._SENT Differential_JJ subcellular_JJ localization_NN of_IN wild-type_NN and_CC mutant_JJ BMPR-II_NP ._SENT Subcellular_JJ distribution_NN of_IN FLAG-tagged_NP wild-type_NP (_( A_NP )_) ,_, E1_NP (_( B_NP )_) ,_, K1_NP (_( C_NP )_) ,_, K2_NP (_( D_NP )_) ,_, or_CC T1_NP (_( E_NP )_) mutant_JJ BMPR-II_NP in_IN transfected_JJ COS-7_JJ cells_NNS ._SENT Permeabilized_JJ cells_NNS were_VBD subjected_VBN to_TO immunofluorescence_VB (_( fluorescein_NN isothiocyanate_NN ;_: green_JJ )_) staining_VBG and_CC observation_NN by_IN confocal_JJ laser_NN scanning_VBG microscopy_NN after_IN nuclear_JJ staining_VBG with_IN 4,6-diamidino-2-phenylindole_JJ (_( red_JJ )_) ._SENT E1_NP and_CC K1_NP Mutants_NP Are_VBP Retained_JJ in_IN the_DT Intracellular_JJ Compartments_NNS with_IN Type_NP I_NP Receptors_NP |_SYM Many_JJ membrane_NN and_CC secreted_VBN proteins_NNS are_VBP posttranslationally_RB modified_VBN by_IN the_DT addition_NN of_IN N-linked_JJ oligosaccharides_NNS ._SENT We_PP expected_VBD that_IN the_DT altered_JJ subcellular_JJ localization_NN of_IN E1_NP and_CC K1_NP mutants_NNS would_MD be_VB confirmed_VBN by_IN their_PP$ posttranslational_JJ modification_NN ._SENT The_DT E1_JJ mutant_JJ protein_NN was_VBD observed_VBN as_IN a_DT fast-migrating_VBG band_NN compared_VBN with_IN WT_NP (_( Figure_NP ,_, bottom_JJ )_) ,_, suggesting_VBG that_IN the_DT E1_JJ protein_NN is_VBZ retained_VBN in_IN the_DT intracellular_JJ compartments_NNS as_IN a_DT glycoprotein_NN containing_VBG high-mannose-type_NN oligosaccharides_NNS ._SENT The_DT K1_NP mutant_NN was_VBD observed_VBN as_IN two_CD bands_NNS ,_, i.e._FW ,_, a_DT fast-migrating_VBG band_NN similar_JJ to_TO the_DT E1_JJ mutant_NN and_CC a_DT slowly_RB migrating_VBG band_NN similar_JJ to_TO the_DT BMPR-II_NP (_( WT_NP )_) protein_NN ._SENT This_DT finding_NN suggests_VBZ that_IN a_DT considerable_JJ portion_NN of_IN the_DT K1_NP mutant_NN is_VBZ also_RB retained_VBN in_IN the_DT intracellular_JJ compartments_NNS ._SENT Figure_NP 6_CD |_SYM Hetero-oligomerization_NN of_IN FLAG-tagged_NP BMPR-II_NP with_IN HA-tagged_NP ALK-3_NP in_IN transfected_JJ COS-7_JJ cells_NNS ._SENT Hetero-oligomerization_NN of_IN FLAG-tagged_NP BMPR-II_NP with_IN HA-tagged_NP ALK-3_NP in_IN transfected_JJ COS-7_JJ cells_NNS ._SENT Top_JJ ,_, cell_NN lysates_NNS were_VBD immunoprecipitated_VBN with_IN anti-FLAG_NN antibody_NN followed_VBN by_IN immunoblotting_VBG with_IN anti-HA_NN antibody_NN ._SENT Expression_NN of_IN ALK-3_NP (_( middle_NN )_) and_CC BMPR-II_NP (_( bottom_NN )_) was_VBD confirmed_VBN by_IN immunoblotting_VBG of_IN cell_NN lysates_NNS with_IN anti-FLAG_NN and_CC anti-HA_NN antibodies_NNS ,_, respectively_RB ._SENT Fast-_NP and_CC slowly_RB migrating_VBG bands_NNS of_IN BMPR-II_NP and_CC ALK-3_NP are_VBP indicated_VBN by_IN open_JJ and_CC closed_JJ triangles_NNS ,_, respectively_RB ._SENT To_TO determine_VB how_WRB the_DT altered_JJ subcellular_JJ localization_NN of_IN the_DT BMPR-II_NP mutants_NNS affects_VBZ complex_JJ formation_NN with_IN type_NN I_PP receptors_NNS ,_, we_PP examined_VBD the_DT hetero-oligomerization_NN of_IN BMPR-II_NP mutants_NNS with_IN ALK-3_NP ._SENT COS-7_JJ cells_NNS cotransfected_VBN with_IN ALK-3_NP and_CC wild-type_NN or_CC mutant_JJ forms_NNS of_IN BMPR-II_NP were_VBD subjected_VBN to_TO FLAG-immunoprecipitation_NP for_IN BMPR-II_NP ,_, followed_VBN by_IN HA-immunoblotting_NP for_IN ALK-3_NP ._SENT BMPR-II_NP (_( WT_NP )_) ,_, BMPR-II_NP (_( SH_NP )_) ,_, and_CC the_DT T1_NP mutant_NN formed_VBD complexes_NNS with_IN slowly_RB migrating_VBG forms_NNS of_IN ALK-3_NP ,_, whereas_IN the_DT E1_NP and_CC K1_NP mutants_NNS formed_VBD complexes_NNS predominantly_RB with_IN fast-migrating_VBG forms_NNS of_IN ALK-3_NP ,_, which_WDT may_MD contain_VB high-mannose-type_NN oligosaccharides_NNS (_( Figure_NP ,_, top_JJ )_) ._SENT These_DT results_NNS suggest_VBP that_IN the_DT E1_NP and_CC K1_NP mutants_NNS are_VBP located_VBN in_IN the_DT intracellular_JJ compartments_NNS and_CC that_IN they_PP may_MD preferentially_RB form_VB complexes_NNS with_IN the_DT type_NN I_PP receptors_NNS located_VBN in_IN the_DT same_JJ compartments_NNS ._SENT Roles_NNS of_IN BMP_NP and_CC TGF-beta_NP Signaling_NP in_IN Maintenance_NP of_IN Vascular_NP Systems_NPS |_SYM TGF-beta_NP plays_VBZ important_JJ roles_NNS during_IN yolk_NN sac_NN vasculogenesis_NN as_RB well_RB as_IN late_JJ stages_NNS of_IN angiogenesis_NN by_IN growth_NN inhibition_NN and_CC production_NN of_IN extracellular_JJ matrix_NN of_IN endothelial_JJ cells_NNS ._SENT In_IN endothelial_JJ cells_NNS ,_, two_CD types_NNS of_IN TGF-beta_NP type_NN I_PP receptors_NNS ,_, ALK-1_NP and_CC ALK-5_NP ,_, mediate_VBP TGF-beta_NP signaling_VBG ._SENT ALK-5_NP is_VBZ ubiquitously_RB expressed_VBN in_IN TGF-beta_NP --_: responsive_JJ cells_NNS and_CC activates_VBZ Smad2_NP and_CC Smad3_NP ._SENT In_IN contrast_NN ,_, ALK-1_NP is_VBZ predominantly_RB expressed_VBN in_IN endothelial_JJ cells_NNS and_CC activates_VBZ BMP-specific_NP Smad1_NP and_CC Smad5_NP ._SENT These_DT observations_NNS suggest_VBP that_IN balance_NN between_IN Smad1/5/8_NP and_CC Smad2/3_NP pathways_NNS is_VBZ important_JJ in_IN determining_VBG vascular_JJ endothelial_JJ properties_NNS during_IN angiogenesis_NN ._SENT Endoglin_NP is_VBZ a_DT dimeric_JJ glycoprotein_NN with_IN a_DT short_JJ intracellular_JJ region_NN that_WDT is_VBZ structurally_RB similar_JJ to_TO betaglycan_NN (_( also_RB known_VBN as_IN TGF-beta_NP type_NN III_NP receptor_NN )_) ._SENT Endoglin_NP binds_VBZ TGF-beta_NP as_RB well_RB as_IN BMP-2_NP and_CC BMP-7_NP ,_, suggesting_VBG that_IN it_PP may_MD regulate_VB both_DT TGF-beta_NP and_CC BMP_NP signaling_VBG pathways_NNS ._SENT Interestingly_RB ,_, mutations_NNS of_IN ALK-1_NP and_CC endoglin_NP have_VBP been_VBN found_VBN in_IN patients_NNS with_IN hereditary_JJ hemorrhagic_JJ telangiectasia_NN ._SENT Taken_VBN together_RB with_IN the_DT findings_NNS that_IN the_DT BMPR2_NP gene_NN is_VBZ mutated_VBN in_IN PPH_NN patients_NNS ,_, our_PP$ findings_NNS suggest_VBP that_IN TGF-beta/BMP_NP signals_NNS mediated_VBN by_IN Smad1_NP ,_, 5_CD ,_, and_CC 8_CD may_MD play_VB important_JJ roles_NNS in_IN maintenance_NN of_IN vascular_JJ homeostasis_NN ._SENT Recently_RB ,_, showed_VBD that_IN PASMCs_NP express_VB receptors_NNS for_IN TGF-beta_NP and_CC BMPs_NP ,_, and_CC that_IN BMP_NP suppressed_VBD the_DT DNA_NN synthesis_NN and_CC proliferation_NN of_IN PASMCs_NNS from_IN patients_NNS with_IN secondary_JJ pulmonary_JJ hypertensions_NNS ,_, but_CC did_VBD not_RB suppress_VB those_DT from_IN patients_NNS with_IN PPH_NP ._SENT The_DT present_JJ study_NN showed_VBD that_IN both_DT HPAECs_NP and_CC PASMCs_NP express_VBP most_JJS of_IN the_DT signaling_VBG components_NNS required_VBN for_IN TGF-beta/BMP_NP signal_NN transduction_NN ,_, including_VBG ligands_NNS ,_, receptors_NNS ,_, and_CC Smads_NNS ._SENT However_RB ,_, response_NN to_TO TGF-beta_NP and_CC BMPs_NP may_MD differ_VB between_IN HPAECs_NP and_CC PASMCs_NP ._SENT Because_IN HPAECs_NP express_VBP both_DT ALK-5_NP and_CC ALK-1_NP ,_, TGF-beta_NP may_MD activate_VB Smad2/3_NP and_CC Smad1/5_NP pathways_NNS ,_, similar_JJ to_TO other_JJ endothelial_JJ cells_NNS ._SENT Because_IN PASMCs_NP do_VBP not_RB express_VB ALK-1_NP ,_, the_DT Smad1/5_NP pathways_NNS may_MD not_RB be_VB activated_VBN by_IN TGF-beta_NP ._SENT Intriguingly_RB ,_, HPAECs_NNS express_VBP ALK-2_NP and_CC ALK-6_NP ,_, but_CC not_RB ALK-3_NP ,_, suggesting_VBG that_IN they_PP respond_VB to_TO BMP-6_NP and_CC BMP-7_NP through_IN ALK-2_NP and_CC ALK-6_NP ,_, but_CC not_RB to_TO BMP-4_NP ,_, which_WDT binds_VBZ to_TO ALK-3_NP ._SENT In_IN contrast_NN ,_, PASMCs_NP express_JJ ALK-2_NP ,_, 3_CD ,_, and_CC 6_CD ,_, suggesting_VBG that_IN they_PP respond_VB to_TO BMP-6_NP and_CC -7_CD as_IN well_RB as_RB to_TO BMP-4_NP ._SENT One_CD of_IN the_DT features_NNS of_IN PPH_NP is_VBZ overproliferation_NN of_IN endothelial_JJ cells_NNS and_CC smooth_JJ muscle_NN cells_NNS ._SENT Taken_VBN together_RB with_IN results_NNS of_IN previous_JJ studies_NNS showing_VBG that_IN BMPs_NNS have_VBP growth_NN inhibitory_JJ effects_NNS on_IN smooth_JJ muscle_NN cells_NNS ,_, these_DT findings_NNS suggest_VBP that_IN it_PP is_VBZ likely_JJ that_IN BMP_NN signals_NNS maintain_VBP pulmonary_JJ vascular_JJ integrity_NN by_IN suppressing_VBG the_DT overproliferation_NN of_IN cells_NNS and_CC that_DT reduction_NN of_IN BMP_NN signals_NNS caused_VBN by_IN mutations_NNS of_IN the_DT BMPR2_NP gene_NN eventually_RB results_VBZ in_IN symptoms_NNS of_IN PPH_NP ._SENT How_WRB Did_VBD Type_NP E_NP and_CC K_NP Mutants_NP Lose_NP Their_PP$ Signal-transducing_NP Abilities_NP ?_SENT |_SYM In_IN the_DT present_JJ study_NN ,_, we_PP generated_VBD five_CD BMPR-II_NP mutants_NNS ,_, i.e._FW ,_, those_DT mutated_VBN in_IN the_DT extracellular_JJ domain_NN (_( E1_NP )_) ,_, kinase_NN domain_NN (_( K1_NP and_CC K2_NP )_) ,_, or_CC cytoplasmic_JJ tail_NN (_( T1_NP and_CC T2_NP )_) (_( Figure_NP A_NP )_) ,_, to_TO examine_VB the_DT biological_JJ activities_NNS of_IN the_DT BMPR-II_NP mutants_NNS found_VBD in_IN PPH_NN patients_NNS ._SENT We_PP found_VBD that_IN the_DT type_NN E_NN and_CC K_NN mutants_NNS lost_VBD their_PP$ transcriptional_JJ activities_NNS ,_, whereas_IN the_DT type_NN T_NN mutants_NNS maintained_VBD transcriptional_JJ activities_NNS although_IN they_PP were_VBD less_RBR potent_JJ than_IN those_DT of_IN BMPR-II_NP (_( WT_NP )_) ._SENT This_DT suggests_VBZ that_IN these_DT BMPR-II_NP mutants_NNS have_VBP different_JJ biological_JJ activities_NNS ._SENT To_TO date_NN ,_, all_DT missense_NN mutations_NNS within_IN the_DT extracellular_JJ domain_NN of_IN BMPR-II_NP have_VBP been_VBN found_VBN at_IN cysteine_NN residues_NNS in_IN PPH_NN patients_NNS ._SENT Interestingly_RB ,_, extracellular_JJ cysteine_NN residues_NNS have_VBP been_VBN shown_VBN to_TO be_VB essential_JJ for_IN formation_NN of_IN proper_JJ three-dimensional_JJ structure_NN and_CC to_TO be_VB required_VBN for_IN membrane_NN targeting_VBG of_IN some_DT receptors_NNS ._SENT Consistent_JJ with_IN this_DT ,_, we_PP found_VBD that_IN most_JJS of_IN the_DT E1_JJ mutant_JJ proteins_NNS mutated_VBN at_IN cysteine-118_NN were_VBD present_JJ in_IN the_DT cytoplasm_NN (_( Figure_NP B_NP )_) ._SENT These_DT results_NNS suggest_VBP that_IN loss_NN of_IN signal-transducing_NN abilities_NNS due_JJ to_TO missense_NN mutations_NNS in_IN the_DT extracellular_JJ ligand-binding_NN region_NN is_VBZ due_JJ not_RB only_RB to_TO loss_NN of_IN ligand-binding_VBG ability_NN of_IN the_DT extracellular_JJ domain_NN but_CC also_RB to_TO altered_JJ subcellular_JJ localization_NN ._SENT Notably_RB ,_, the_DT E1_JJ mutant_JJ protein_NN migrated_VBD faster_RBR than_IN the_DT BMPR-II_NP (_( WT_NP )_) protein_NN (_( Figure_NP ,_, bottom_JJ )_) ,_, implying_VBG differential_JJ posttranslational_JJ modification_NN due_JJ to_TO abnormal_JJ subcellular_JJ localization_NN of_IN the_DT E1_JJ protein_NN ._SENT When_WRB ALK-3_NP was_VBD coexpressed_VBN with_IN the_DT E1_JJ mutant_NN ,_, only_RB fast-migrating_VBG protein_NN bands_NNS of_IN ALK-3_NP formed_VBD complexes_NNS with_IN the_DT E1_JJ mutant_JJ proteins_NNS (_( Figure_NP ,_, top_JJ )_) ._SENT Many_JJ membrane-targeted_JJ proteins_NNS are_VBP posttranslationally_RB modified_VBN by_IN addition_NN of_IN N-linked_JJ oligosaccharides_NNS during_IN transport_NN through_IN the_DT Golgi_NP apparatus_NN ._SENT Treatment_NN of_IN ALK-3_NP and_CC BMPR-II_NP with_IN N-glycosidase_NP F_NP resulted_VBD in_IN shift_NN of_IN slowly_RB migrating_VBG bands_NNS of_IN ALK-3_NP and_CC BMPR-II_NP to_TO fast-migrating_JJ bands_NNS (_( our_PP$ unpublished_JJ data_NNS )_) ,_, suggesting_VBG that_IN the_DT fast-migrating_VBG proteins_NNS of_IN the_DT E1_JJ mutant_NN and_CC ALK-3_NP may_MD contain_VB high-mannose-type_NN oligosaccharides_NNS and_CC that_IN they_PP are_VBP retained_VBN in_IN the_DT cytoplasm_NN as_IN a_DT complex_NN ._SENT These_DT results_NNS raised_VBD the_DT possibility_NN that_IN dominant_JJ negative_JJ effects_NNS of_IN the_DT E1_JJ mutant_NN against_IN BMPR-II_NP (_( WT_NP )_) may_MD be_VB due_JJ to_TO sequestration_NN of_IN BMP_NN type_NN I_PP receptors_NNS in_IN the_DT intracellular_JJ compartments_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, missense_NN mutations_NNS within_IN the_DT kinase_NN region_NN were_VBD identified_VBN at_IN various_JJ amino_NN acid_NN residues_NNS ,_, including_VBG cysteine_NN ,_, aspartic_JJ acid_NN ,_, and_CC arginine_NN residues_NNS ._SENT The_DT K1_NP mutant_NN ,_, with_IN substitution_NN of_IN cysteine-347_JJ by_IN tyrosine_NN ,_, exhibited_VBD a_DT reduced_VBN ligand-binding_NN ability_NN than_IN BMPR-II_NP (_( WT_NP )_) ._SENT This_DT can_MD be_VB explained_VBN by_IN the_DT distribution_NN of_IN mutant_JJ proteins_NNS partially_RB in_IN cytoplasm_NN ,_, as_RB demonstrated_VBN by_IN immunohistochemical_JJ analysis_NN and_CC by_IN the_DT presence_NN of_IN fast-migrating_VBG bands_NNS on_IN immunoblot_NN analysis_NN (_( Figures_NP C_NP and_CC ,_, bottom_JJ )_) ._SENT However_RB ,_, this_DT distribution_NN profile_NN of_IN the_DT K1_NP mutant_JJ proteins_NNS cannot_MD fully_RB explain_VB the_DT loss_NN of_IN signal-transducing_VBG ability_NN and_CC gain_NN of_IN dominant_JJ negative_JJ activity_NN by_IN them_PP ,_, which_WDT were_VBD equivalent_JJ to_TO those_DT of_IN the_DT E1_JJ mutant_NN ._SENT Kinase_NN activity_NN was_VBD probably_RB lost_VBN in_IN the_DT K1_NP mutant_NN ,_, resulting_VBG in_IN the_DT potent_JJ dominant_JJ negative_JJ effects_NNS of_IN this_DT mutant_NN ._SENT In_IN agreement_NN with_IN this_DT ,_, a_DT BMPR-II_NP kinase_NN negative_JJ mutant_NN exhibited_VBD a_DT dominant_JJ negative_JJ effect_NN against_IN ActR-II_NP in_IN transcriptional_JJ activation_NN activity_NN ._SENT The_DT K2_NP mutant_NN ,_, with_IN substitution_NN of_IN aspartic_JJ acid-485_NN by_IN glycine_NN ,_, exhibited_VBN normal_JJ ligand-binding_NN ability_NN and_CC subcellular_JJ localization_NN (_( Figure_NP D_NP )_) ,_, but_CC lost_VBD signal-transducing_NN ability_NN (_( Figure_NP B_NP )_) ._SENT Kinase_NN activity_NN was_VBD probably_RB lost_VBN in_IN the_DT K2_NP mutant_NN ,_, which_WDT may_MD have_VB caused_VBN the_DT loss_NN of_IN transcriptional_JJ activity_NN ;_: however_RB ,_, how_WRB the_DT K2_NP mutant_NN has_VBZ less_RBR dominant_JJ negative_JJ effect_NN remains_VBZ unknown_JJ ._SENT Role_NN of_IN BMPR-II_NP Mutants_NP with_IN Truncation_NP of_IN Cytoplasmic_NP Tail_NP in_IN Pathogenesis_NP of_IN PPH_NP |_SYM BMPR-II_NP is_VBZ structurally_RB similar_JJ to_TO other_JJ type_NN II_CD receptors_NNS of_IN the_DT TGF-beta_NP superfamily_NN ,_, e.g._FW ,_, TbetaR-II_NP ,_, ActR-IIA_NNS ,_, and_CC ActR-IIB_NP ._SENT However_RB ,_, BMPR-II_NP has_VBZ a_DT long_JJ cytoplasmic_JJ tail_NN that_WDT is_VBZ not_RB found_VBN in_IN other_JJ type_NN II_CD receptors_NNS in_IN mammals_NNS ._SENT The_DT functions_NNS of_IN the_DT cytoplasmic_JJ tail_NN of_IN BMPR-II_NP are_VBP not_RB yet_RB clear_JJ ._SENT The_DT fact_NN that_IN truncation_NN of_IN the_DT cytoplasmic_JJ tail_NN of_IN BMPR-II_NP was_VBD found_VBN in_IN type_NN T_NN mutants_NNS from_IN patients_NNS with_IN PPH_NP suggests_VBZ novel_JJ functions_NNS for_IN this_DT region_NN ._SENT Compared_VBN with_IN the_DT E1_NP and_CC K1_NP mutants_NNS ,_, however_RB ,_, the_DT T1_NP mutant_NN retained_VBD most_JJS of_IN its_PP$ biological_JJ activity_NN with_IN the_DT exception_NN that_IN it_PP phosphorylated_VBD Smad5_NP less_RBR efficiently_RB than_IN WT_NP or_CC SH_NP forms_NNS of_IN BMPR-II_NP ._SENT analyzed_VBN the_DT transcriptional_JJ activities_NNS of_IN BMPR-II_NP mutants_NNS K2_NP and_CC T1_NP according_VBG to_TO our_PP$ nomenclature_NN ,_, in_IN NMuMG_NP cells_NNS in_IN which_WDT endogenous_JJ BMP_NN signaling_VBG pathways_NNS are_VBP intact_JJ ._SENT Although_IN they_PP concluded_VBD that_IN both_DT of_IN mutants_NNS lost_VBD their_PP$ signaling_VBG capabilities_NNS ,_, their_PP$ results_NNS showed_VBD that_IN only_RB the_DT K2_NP mutant_NN ,_, but_CC not_RB the_DT T1_JJ mutant_NN ,_, inhibited_VBD endogenous_JJ BMP_NN signals_NNS ._SENT Thus_RB ,_, there_EX may_MD be_VB significant_JJ differences_NNS in_IN biological_JJ activities_NNS between_IN the_DT K2_NP and_CC T1_NP mutants_NNS ,_, consistent_JJ with_IN our_PP$ results_NNS ._SENT Recently_RB ,_, showed_VBD that_IN BMPR-II_NP mutants_NNS completely_RB lacking_VBG the_DT cytoplasmic_JJ tail_NN were_VBD capable_JJ of_IN transducing_VBG BMP-2_JJ signals_NNS similar_JJ to_TO BMPR-II_NP (_( SH_NP )_) ._SENT Taken_VBN together_RB with_IN the_DT present_JJ findings_NNS ,_, these_DT results_NNS suggest_VBP that_IN the_DT cytoplasmic_JJ tail_NN of_IN BMPR-II_NP may_MD not_RB be_VB essential_JJ for_IN transduction_NN of_IN BMP_NN signals_NNS through_IN Smads_NNS ,_, although_IN it_PP is_VBZ possible_JJ that_IN it_PP has_VBZ yet_RB unidentified_JJ functions_NNS in_IN BMP_NP signaling_VBG ._SENT It_PP will_MD be_VB important_JJ to_TO determine_VB whether_IN other_JJ factors_NNS ,_, such_JJ as_IN additional_JJ genetic_JJ mutations_NNS and/or_CC environmental_JJ factors_NNS ,_, play_VB important_JJ roles_NNS in_IN the_DT pathogenesis_NN of_IN PPH_NP ._SENT 